Mentholatum Issues Nationwide Recall of Rohto Eye Drops - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Mentholatum Issues Nationwide Recall of Rohto Eye Drops



Mentholatum, a manufacturer of pharmaceuticals, and other healthcare products, is conducting a voluntary recall to the retail level of eye drops made in Vietnam due to a manufacturing review at the production facility in Vietnam involving sterility controls.

The recall includes only lots of Rohto Arctic, Rohto Ice, Rohto Hydra, Rohto Relief, and Rohto Cool eye drops that were manufactured in Vietnam and does not include eye drops made in Japan. Products manufactured in Japan are not included in this recall and continue to be available to consumers.

To date, there has been no evidence indicating that product does not meet specifications; however, the company is taking this action as a precautionary measure.

Source: Mentholatum

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race

Click here